Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone suggests cautious support, with professionals emphasizing the significance of the findings, such as mentions that breast cancer recurrence risk was similar regardless of vaginal estrogen use, while some express ongoing concern and desire for further studies. The choice of words like 'helpful' and references to clinical data reflect a balanced and thoughtful discussion about the article's implications.
Most discussions reflect support or cautious optimism towards the study's findings, especially from medical professionals advocating for vaginal estrogen use.
The social discussions show moderate interest, with many referencing the importance of the issue and the need for ongoing research.
Participants engage by sharing their opinions, referencing clinical evidence, and discussing implications, indicating a moderate depth of interaction.
The conversations could influence clinical practices and patient choices, pointing to a noticeable but not transformative impact.
@Iambeth2 @VioletandPercy @NHSEngland @drrachelrubin Risk of breast cancer recurrence was comparable between those who received vaginal estrogen and those who did not - studied over 40,000 cases. https://t.co/9FcD4QEDaI)%20status%20analyses.
@Kath_leen37 @SarahTevisMD @Liz_ORiordan This may be helpful. https://t.co/2LmUtg6dIY Dr Alison McBeth is a Breast Cancer Dr who prescribes vaginal oestrogen to all her patients because she cares about their QOL, she may be able to advise you x
Further evidence from randomised controlled trials is necessary to improve our understanding of such treatment approaches. Link to paper - https://t.co/pHonDzdsvQ
https://t.co/aOOLWLtcrP
RT @MenoScandal: @Iambeth2 @VioletandPercy @NHSEngland @drrachelrubin Risk of breast cancer recurrence was comparable between those who rec…
@kristinrojasmd - :) https://t.co/RXm5rvoIb3
Topical estrogen creams are popular for antiaging, but they carry potential risks such as breast and uterine cancer and blood clots. This video discusses these benefits and concerns, focusing on safety and usage…
This study assesses the safety of vaginal estrogen therapy for genitourinary syndrome of menopause in women with prior breast cancer. Results show no increased risk of cancer recurrence among women using vaginal…
@Kath_leen37 @SarahTevisMD @Liz_ORiordan This may be helpful. https://t.co/2LmUtg6dIY Dr Alison McBeth is a Breast Cancer Dr who prescribes vaginal oestrogen to all her patients because she cares about their QOL, she may be able to advise you x
RT @MenoScandal: @Iambeth2 @VioletandPercy @NHSEngland @drrachelrubin Risk of breast cancer recurrence was comparable between those who rec…
@Iambeth2 @VioletandPercy @NHSEngland @drrachelrubin Risk of breast cancer recurrence was comparable between those who received vaginal estrogen and those who did not - studied over 40,000 cases. https://t.co/9FcD4QEDaI)%20status%20analyses.
Read the full article at https://t.co/EcSmSUCRTl https://t.co/ellR26Eqjo
Further evidence from randomised controlled trials is necessary to improve our understanding of such treatment approaches. Link to paper - https://t.co/pHonDzdsvQ
Safety of Vaginal Estrogen Therapy for Genitourinary Syndrome of Menopause in Women With a History of Breast Cancer https://t.co/kGgtX5Xmnd Algo es algo, pero no quedo tranquilo con eso!
https://t.co/aOOLWLtcrP
@kristinrojasmd - :) https://t.co/RXm5rvoIb3